Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Secukinumab
Cosentyx
Routinely available
SMC (1159/16)
29/03/2023
Indication
Treatment of active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy.
Therapeutic Area
Musculoskeletal and joint diseases
Status Description
Routinely available in line with national guidance
Formulation
150mg pre-filled syringe, 150mg pre-filled pen
Comments
-